Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innocan Pharma Corp (OP:INNPF)

5.920 UNCHANGED
Streaming Delayed Price Updated: 11:35 AM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Innocan Pharma Corp

News headline image
This Week In Cannabis: Trump Policy Updates, Corporate Moves, Regulatory Shifts And Product Innovations ↗
This week in cannabis: major mergers, innovative launches, key regulatory updates & leadership changes drive industry transformation. 
Via Benzinga
Topics Government
News headline image
Cannabinoid Leader Innocan Pharma's Q3: 174% YoY Revenue Growth ↗
Innocan Pharma reports 174% YoY revenue growth in Q3 2024, driven by innovation in cannabinoids and strong sales from BI Sky Global Ltd. 
Via Benzinga
News headline image
CBD-Focused Innocan Pharma Achieves 4X Revenue Growth In Q1, Hits $6.8M Mark ↗
Innocan Pharma's Q1 2024 revenue surged 334% to $6.8M, driven by strong sales growth from BI Sky Global. Read about financial performance. 
Via Benzinga
News headline image
This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain ↗
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S. Food and Drug Administration... 
Via Benzinga
News headline image
4 CBD Stocks in the Canadian Capital Market ↗
Photo by 
Via Benzinga
News headline image
534% Revenue Surge Unveiled By Israeli CBD-Focused Pharma Company, Exceeding Expectations ↗
Innocan Pharma's 2023 earnings report: Revenue soars 534%, operating loss down 61%, $1.5M capital raise. CEO shares strategic vision. 
Via Benzinga
News headline image
CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval ↗
Cannabinoid-focused pharmaceutical company Innocan Pharma Corp expects preliminary revenues of $4.89m in Q4 of fiscal 2023, representing a YoY increase of 331%. It said preliminary revenues are... 
Via Benzinga
News headline image
Key Leadership Changes In Cannabis You Should Know About As We Head Into 2024 ↗
This month, the Indigenous Cannabis Industry Association held its first Indigenous Cannabis Regulators roundtable, bringing together Indigenous Cannabis Regulators from Tribal Nations and... 
Via Benzinga
Topics Cannabis
News headline image
More Cannabis Funding For FDA And Product Expansion: How This Pharma Tech Company Is Doing It ↗
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) has closed the second and final tranche of its previously announced private placement offering of its units. 
Via Benzinga
Topics Cannabis
News headline image
CBD-Focused Pharma Co. Seeks Funding To Revolutionize Healthcare ↗
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) has entered into an agreement with Research Capital Corporation as the sole agent and sole book-runner on a "best efforts" agency basis... 
Via Benzinga
News headline image
Innocan Pharma's Q2 2023 Reports Gross Profit Growth Driven By Robust Subsidiary Sales ↗
Innocan Pharma Corporation (CSE: INNO)(FSE: IP4) (OTC: INNPF), a pharmaceutical technology firm specializing in innovative drug delivery platforms, 
Via Benzinga
News headline image
Innocan Pharma Secures $1.4M Via Private Placement ↗
Innocan Pharma Corporation (OTC: INNPF) (CSE:INNO) (FSE:IP4) has closed a non-brokered private placement offering of 8.4 million units of Innocan at a price of CA$0.23 per unit 
Via Benzinga
News headline image
Innocan Pharma To Secure Up To $3M Via Private Placement Of Units At A 9% Prime Above Share Price ↗
Innocan Pharma Corporation (OTCQB: INNPF) (CSE:INNO) (FSE:IP4) intends to complete a non-brokered private placement of up to 17.22 million units of the company at a price of CA$0.23 per unit fo 
Via Benzinga
News headline image
Cannabis Stock Gainers And Losers From August 25, 2023 ↗
 
Via Benzinga
Topics Cannabis
News headline image
Cannabis Stock Movers For July 21, 2023 ↗
 
Via Benzinga
News headline image
Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023 ↗
 
Via Benzinga
Topics Cannabis
News headline image
Innocan Pharma Q1 Revenue Grows 500%, Here Is What You Need To Know ↗
Innocan Pharma Corporation (OTCQB: INNPF) (CSE:INNO) (FSE:IP4) released its financial results for the three months ended March 31, 2023, revealing revenue of $1.6 million, an increase of 500%, 
Via Benzinga
News headline image
Innocan Pharma FY22 Revenue Grows 1205% To $2.6M, Here Is What You Need To Know ↗
Innocan Pharma Corporation (OTCQB: INNPF) (CSE:INNO) (FSE:IP4) released its audited financial results for the year ended December 31,2022, revealing revenue of $2.6 million, an increase of 1205% from... 
Via Benzinga
News headline image
Bullish Thursday For Marijuana Stocks - EVIO, Tetra Bio Pharma Among Top Gainers ↗
 
Via Benzinga
Topics Cannabis
News headline image
Can Liposomal CBD Injection Help Dogs With Polyarthritis? Innocan Pharma Reports Clinical Success ↗
Innocan Pharma Corporation (OTCQB: INNPF) (CSE:INNO) (FSE:IP4) reported clinical success in its Canine (dogs) Compassionate Care Trial, resulting in improving walking abilities and significant decrease... 
Via Benzinga
News headline image
Innocan Pharma Q3 Revenue Grows 700% YoY, Here Is What You Need To Know ↗
Innocan Pharma Corporation (OTCQB: INNPF) (CSE:INNO) (FSE:IP4) released its financial results for the three and nine months ended September 30, 2022, revealing Q3 revenue of $1.42 million, a 700% 
Via Benzinga
News headline image
Cannabis Stock Gainers And Losers From August 14, 2023 ↗
 
Via Benzinga
Topics Cannabis
News headline image
Cannabis Stock Gainers And Losers From August 11, 2023 ↗
 
Via Benzinga
Topics Cannabis
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.